N,N'-Dinitrosopiperazine
Based on 1 Customer Validation
N,N'-Dinitrosopiperazine (1,4-Dinitrosopiperazine; DNP) is a carcinogen with specificity for nasopharyngeal epithelium and facilitates NPC metastasis. N,N'-Dinitrosopiperazine regulates multiple signaling pathways through protein phosphorylation, including LYRIC at serine 568.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.96%
- CAS No.: 140-79-4
- Formule: C4H8N4O2
- Masse moléculaire:144.13
-
Stockage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Bioactive Compound Library Max
HY-L181
-
Bioactive Compound Library
HY-L001
-
Anti-Cancer Compound Library
HY-L025
-
Tumorigenesis-Related Compound Library
HY-L100
-
Human Metabolite Library
HY-L123
-
Mitochondrial Protection Compound Library
HY-L144
-
MCE Bioactive Compound Library
HY-L001V
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
Activité biologique
N,N'-Dinitrosopiperazine (0.5-100 μM; 48 hours) has no inhibitory effects on the labeled 6-10B cells, and LDH activity is not significantly altered by DNP treatment in the 0.5-8 μM concentration range. However, it is cytotoxic from the concentration 10 μM[1].N,N'-Dinitrosopiperazine (2-8 μM; 24 hours) induces 6-10B cell invasion and motility in a dose-dependent manner. At 6 μM, when compares to the control group, DNP increases cell invasion at 421.7% and cell motility is increased by 328.2%[1].N,N'-Dinitrosopiperazine (6 μM; 24 hours) increases the expression of phospho-LYRIC s568 and LYRIC expression in CNE1 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:The labeled 6-10B cells
-
Concentration:0.5, 1, 2, 4, 6, 8, 10, 20, 40, 80, or 100 μM
-
Incubation Time:48 hours
-
Result:Had no inhibitory effects at the concentration 0-8 μM.
-
Cell Line:The NPC cell line CNE1
-
Concentration:6 μM
-
Incubation Time:24 hours
-
Result:Increased phospho-LYRIC s568 and LYRIC expression.
Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.
N,N'-Dinitrosopiperazine (injected into the tail veins; 40 mg/kg; 30 days) inhibits cell motility and invasion, and facilitates NPC metastasis in vivo. From a IHC result, Phospho-LYRIC expression is higher in the metastatic tumors of DNP-treated mice than in those of the untreated control mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BABL/c nude mice injected with labeled 6-10B cell suspensions (1 × 104 cells) with or without DNP(40 mg/kg)[1]
-
Dosage:40 mg/kg
-
Administration:Injected into the tail veins; 30 days
-
Result:Induced LYRIC phosphorylation at serine 568 associated with NPC metastasis in vivo.
Chemical Information
-
CAS No. 140-79-4
-
Appearance Solid
-
Masse moléculaire 144.13
-
Formule C4H8N4O2
-
Color White to off-white
-
SMILES
O=NN1CCN(N=O)CC1
-
Synonyms
1,4-Dinitrosopiperazine; DNP
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Solvant et solubilité
DMSO : 100 mg/mL (693.82 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (17.35 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (17.35 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (273 KB)
-
SDS (645 KB)
- English - EN (645 KB)
- Français - FR (645 KB)
- Deutsch - DE (645 KB)
- Norwegian - NO (645 KB)
- Español - ES (645 KB)
- Swedish - SV (645 KB)
- Italian - IT (645 KB)
- Korean - KR (645 KB)
- Portuguese - PT (645 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 6.9382 mL | 34.6909 mL | 69.3818 mL | 173.4545 mL |
| 5 mM | 1.3876 mL | 6.9382 mL | 13.8764 mL | 34.6909 mL | |
| 10 mM | 0.6938 mL | 3.4691 mL | 6.9382 mL | 17.3455 mL | |
| 15 mM | 0.4625 mL | 2.3127 mL | 4.6255 mL | 11.5636 mL | |
| 20 mM | 0.3469 mL | 1.7345 mL | 3.4691 mL | 8.6727 mL | |
| 25 mM | 0.2775 mL | 1.3876 mL | 2.7753 mL | 6.9382 mL | |
| 30 mM | 0.2313 mL | 1.1564 mL | 2.3127 mL | 5.7818 mL | |
| 40 mM | 0.1735 mL | 0.8673 mL | 1.7345 mL | 4.3364 mL | |
| 50 mM | 0.1388 mL | 0.6938 mL | 1.3876 mL | 3.4691 mL | |
| 60 mM | 0.1156 mL | 0.5782 mL | 1.1564 mL | 2.8909 mL | |
| 80 mM | 0.0867 mL | 0.4336 mL | 0.8673 mL | 2.1682 mL | |
| 100 mM | 0.0694 mL | 0.3469 mL | 0.6938 mL | 1.7345 mL |
N,N'-Dinitrosopiperazine Related Classifications
HY-136433 Related Classifications
Powered by Bioz